While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
Shopify debuts a new network to help it compete with Amazon.Marketsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
The strong dollar story could be over for now, and that's putting a shine on the 'anti-dollar' trade—gold.Market Insiderread more
"I believe it would be wise to take additional time and allow events to unfold" before deciding on rates, the Dallas Fed official said in an essay.The Fedread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
An Air Canada passenger traveling to Toronto from a weekend in Quebec City found herself stranded alone on the tarmac and in the dark, in what she described as a "nightmare."Airlinesread more
The new cut will likely draw thousands back to theaters and could finally push "Avengers: Endgame" above and beyond the record $2.78 billion "Avatar" has earned since its...Entertainmentread more
Donald Trump and Xi Jinping are expected to meet at this week's G-20 summit in Japan and the stakes for Wall Street are high.Marketsread more
In his quest to fend off a hostile takeover attempt, has Allergan CEO David Pyott got something powerful up his sleeve?
On "Mad Money" Pyott said the company was about to introduce a major restructuring that could boost shareholder value. "We're taking a deep look to see where we can do some trimming," Pyott said, adding specifics would be outlined in the company's earnings announcement in the weeks ahead. "The only thing I care about is the creation of value for shareholders."
That creation of value is a key issue for , whose shares have surged since late spring, when Valeant made its first of three takeover offers. However, Allergan has refused those offers, in part, arguing that the Valeant business model will diminish value, not enhance it.
"Valeant is a classic roll-up: they acquire other drug companies, then gut any unnecessary expenses to boost profits, which in many cases includes slashing the research and development budget," Cramer explained.
By contrast, Allergan believes in increasing R&D to fuel powerful long-term growth.
"We question the sustainability of the Valeant business model in its entirety," Pyott added. "They would cut R&D 90 percent. That isn't value creation it's value reduction."
And Pyott suggested that even if Valeant were to walk away, shares should hold most of their recent 40 percent advance. "What we've been doing is raising the floor of Allergan as a standalone entity."
Read more from Mad Money with Jim Cramer
3 stocks with big reward potential
Cramer; Don't let these stocks fool you
Cramer: This stock a real bargain
That is, Pyott believes that due to the strength of Allergan pipeline as well as the forthcoming value creation to be announced later this month, current share price is justified and therefore should be sustainable.
"I know the market is waiting to see what we put on the table when we announce earnings. Hopefully they will applaud," Pyott said.
In an interview with the Wall Street Journal, Pyott also indicated his company was looking at potential acquisitions, although he declined to get into specifics.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com